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Background: Adalimumab (Ada) treatment is an available option for pediatric Crohn’s disease 
(CD) and the published experience as rescue therapy is limited.
Objectives: We investigated Ada efficacy in a retrospective, pediatric CD cohort who had failed 
previous infliximab treatment, with a minimum follow-up of 6 months.
Methods: In this multicenter study, data on demographics, clinical activity, growth, laboratory 
values (CRP) and adverse events were collected from CD patients during follow-up. Clinical 
remission (CR) and response were defined with Pediatric CD Activity Index (PCDAI) score 
≤10 and a decrease in PCDAI score of ≥12.5 from baseline, respectively.
Results: A total of 44 patients were consecutively recruited (mean age 14.8 years): 34 of 44 
(77%) had active disease (mean PCDAI score 24.5) at the time of Ada administration, with a 
mean disease duration of 3.4 (range 0.3–11.2) years. At 6, 12, and 18 months, out of the total 
of the enrolled population, CR rates were 55%, 78%, and 52%, respectively, with a significant 
decrease in PCDAI scores (P<0.01) and mean CRP values (mean CRP 5.7 and 2.4 mL/dL, 
respectively; P<0.01) at the end of follow-up. Steroid-free remission rates, considered as the 
total number of patients in CR who were not using steroids at the end of this study, were 93%, 
95%, and 96% in 44 patients at 6, 12, and 18 months, respectively. No significant differences 
in growth parameters were detected. In univariate analysis of variables related to Ada efficacy, 
we found that only a disease duration >2 years was negatively correlated with final PCDAI 
score (P<0.01). Two serious adverse events were recorded: 1 meningitis and 1 medulloblastoma.
Conclusion: Our data confirm Ada efficacy in pediatric patients as second-line biological 
therapy after infliximab failure. Longer-term prospective data are warranted to define general 
effectiveness and safety in pediatric CD patients.
Keywords: pediatric Crohn’s disease, infliximab failure, adalimumab efficacy, adalimumab 
safety
Introduction
Crohn’s disease (CD) is a chronic, relapsing disease of the gastrointestinal tract affect-
ing mainly young patients. In the past few decades, its incidence rate in the pediatric 
population has increased to 0.1–13.9 per 100,000 persons.1 Pediatric CD is charac-
terized by frequent relapses, a wide extent of disease, a severe clinical course, and a 
high prevalence of extraintestinal manifestations. Almost a third of affected children 
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present moderate–severe disease requiring a more aggres-
sive therapeutic strategy to induce and maintain remission. 
However, treating CD is a major challenge for clinicians, as 
no curative therapy currently exists. Conventional therapy 
includes the use of corticosteroids, which are very effective 
and fast-acting; however, long-term exposure leads to drug 
dependence and/or resistance.2 Furthermore, corticosteroids 
carry a substantial risk of developing side effects, with growth 
retardation being one of the major concerns in pediatric 
CD patients.2,3 Immunomodulators, such as thiopurines and 
methotrexate, have proved to be effective in maintaining CD 
remission and sparing steroids.4,5 In particular, thiopurines are 
successful in about 70% of CD patients,6 but still primary or 
secondary nonresponders need alternative treatment.
Anti-TNFα antibodies represent a valid therapeutic 
option for pediatric patients affected by CD disease. Indeed, 
infliximab (Ifx) has been thoroughly evaluated in the past 
decade, with first data published in 2007.7 However, it has 
been shown that not all patients initially respond to Ifx (ie, 
primary failure), and a subset of patients discontinue Ifx as a 
consequence of loss of response or intolerance (ie, secondary 
failure).8 Recent data report that about 30% of patients lose 
response within 3 years after starting Ifx and almost 50% need 
dose escalation.9,10 Also, adalimumab (Ada) has demonstrated 
its effectiveness in treating CD patients in randomized clini-
cal trials carried out in both adult and pediatric patients.11–16 
However, since Ada was definitively approved by the Euro-
pean Medicines Agency for pediatric CD only in November 
2012, real-life data on Ada clinical efficacy, its effect on 
growth status, and its safety profile are scarce, especially 
in patients who have failed Ifx therapy. The purpose of our 
study consisted in assessing the safety and efficacy of Ada 
as a second-line biological therapy in pediatric CD patients 
who had failed or were intolerant to Ifx.
Methods
Study design
We performed a retrospective, multicenter, cohort analysis 
of 44 CD pediatric patients with moderate–severe CD activ-
ity who had been treated with Ifx and were switched to Ada 
because of primary or secondary failure in 13 Italian pediatric 
gastroenterology centers. These centers were geographically 
well distributed throughout the country and were all affili-
ated with the Italian Society of Pediatric Gastroenterology, 
Hepatology, and Nutrition (SIGENP). All SIGENP centers 
were recruited by email correspondence and a questionnaire 
provided to the participants in autumn 2014. A new recall 
was made in April 2015 further to obtain the most recent 
follow-up data. Data collection was authorized by the eth-
ics committees and written informed consent obtained for 
each study subject by parents. This study was conducted in 
accordance with the Declaration of Helsinki.
Patients
To be eligible for the study, patients had to fulfill criteria of 
CD diagnosed according to the recognized international cri-
teria,17 age <18 years at the time of first Ada administration, 
disease location defined by the Paris classification,18 primary 
or secondary failure to Ifx treatment, and a follow-up of at 
least 6 months. In cases of secondary failure, loss of response 
was defined as an increase in Pediatric CD Activity Index 
(PCDAI) score compared to baseline, whereas subjects were 
deemed intolerant once they had experienced a clinically 
significant acute (within 24 hours) or delayed (>24 hours, 
but within 15 days) infusion reaction.
Study outcomes
The primary end point was to evaluate Ada clinical efficacy 
in the studied population through assessing PCDAI scores 
at 6, 12, and 18 months. Secondary end points included the 
collection of adverse events, changes in CRP, and weight 
and growth trends during a follow-up of at least 18 months. 
Clinical complete remission was defined by a PCDAI score 
≤10, clinical response for PCDAI score >10, and a decrease 
in PCDAI score ≥12.5 points from baseline, because a 
decrease in PCDAI of 12.5 points has been revealed as 
the smallest change associated with physician assessment 
of at least moderate improvement, and thus the best value 
to be used, in order to capture both clinical remission and 
clinical response.19–21 No response in the case of persistently 
active disease was defined by a PCDAI score ≥10 or by a 
decrease in PCDAI score <12.5 points assessed at different 
times points throughout the study and in cases of relapse. 
Steroid-free remission consisted in clinical remission 
without the use of budesonide or other steroids. Steroid 
dependency was defined as the inability to stop systemic 
steroids within 3 months, or recurrence within 3 months 
from steroid withdrawal.
Data collected included demographics, disease 
extension, phenotype (Paris classification), presence of 
perianal disease, PCDAI, body-mass index (BMI), height, 
previous and concomitant medications (corticosteroids, 
immunomodulators), data regarding previous Ifx therapy 
(dosage, duration, treatment response, reasons for 
discontinuation), and dose escalation related to Ada therapy. 
All anthropometric data were converted into SD scores 
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calculated on the basis of Italian growth-chart references and 
are expressed as means ± SD. Data on growth and weight 
were specifically recorded at diagnosis (T0), when Ada was 
initiated (Ada start), and at 6 (T6) and 18 months (T18). 
Disease severity, defined according to PCDAI score, and 
treatments were analyzed in relation to growth measures. 
Acute and delayed (reaction >24 hours after drug injection) 
intolerance toward Ada was evaluated. In addition, adverse 
events were reported by each center’s investigators.
Statistical analysis
All data were summarized and are displayed as means ± SD 
for continuous variables.22 Categorical data are expressed 
as frequencies and percentages, while possible missing data 
have been excluded from the analysis. In order to compare 
mean values of PCDAI scores at different moments of the 
study, Student’s t-test was implemented for paired samples, 
with equality in PCDAI mean values at different times the 
null hypothesis. Fisher’s exact test was used to compare 
potential prognostic factors for positive or negative responses 
at follow-ups. This choice was due to the limited number of 
statistical units, which prevented us from safely using stan-
dard parametric tests to investigate the proportion of subjects 
in remission at different times during the course of the study 
in the two groups of each identified prognostic factor. Still, 
despite the reduced number of units, Kaplan–Meier survival 
analyses with log-rank tests were run to show the trend of 
length of stay in the study of such cohort. The P-value was 
set at 0.05 for significance for all statistical tests. Finally, 
moving from a one-dimensional to a multidimensional 
approach, a multiple logistic model with positive or negative 
response at each follow-up as dependent variables was used 
for multivariate analysis.
Results
Demographic and clinical data at baseline
A total of 44 of 56 CD patients (78%) were enrolled, with 
the 12 excluded because they did not meet the inclusion 
criteria: eight were older than 18 years when Ada therapy 
was started, three had had follow-up <6 months, and one 
was anti-TNF-naïve. The main baseline characteristics of the 
CD patients are summarized in Table 1. The whole cohort 
had previously been treated with Ifx at the standard dose of 
5 mg/kg every 8 weeks after induction. The mean number 
of infusions was nine (two to 28) for an average treatment 
period of 12 months. Ifx was adopted as first-line therapy 
in eight of 44 (18%), whereas 35 (80%) where treated after 
immunomodulator failure. One patient (2%) received Ifx 
after failure of both immunomodulators and thalidomide. In 
23 cases (52%), Ifx was discontinued due to loss of efficacy 
(three of 23 primary nonresponders, 20 of 23 secondary 
nonresponders), whereas 21 (48%) stopped Ifx because of 
related adverse events.
Adalimumab data
Treatment
Mean age at first Ada injection was 14.8 (range 9.9–17.1, 
median 14.7) years, with mean time from CD diagnosis of 
3.4 years (4 months to 11.2 years, median 3.5 years). Mean 
follow-up was 12 (range 6–18) months. At baseline, of 44 
patients, 34 (77%) had active disease according to their 
PCDAI score (mean 24.9), whereas ten patients (23%) were 
in clinical remission. Dosage was based on body weight. A 
total of 34 patients (77%) received a subcutaneous loading-
dose regimen at weeks 0 and 2 as induction. In the 34 patients 
with active disease, the loading dose consisted of 80 mg/40 
mg in 19 patients, 160 mg/80 mg in ten, and 120 mg/80 mg 
in five. The remaining ten patients were in clinical remission, 
Table 1 Patient demographics at diagnosis and treatment before 
Ada
n (%)
Sex
Female 23 (52)
Male 21 (48)
Age, years (range 9.9–17.1)
Mean 10.9
Median 11.1
PCDAI score
≥40 24 (54.5)
30–39 13 (29.5)
11–29 6 (13.6)
≤10 1 (2.4)
Disease location (Paris classification)
Terminal ileum (L1) 5 (11)
Colonic (L2) 8 (18)
Ileocolonic (L3) 10 (23)
Ileum and colonic and gastroduodenal disease  
(L3 + L4B)
17 (39)
Disease behavior
No stricture or penetration (B1) 40 (91)
Stricture (B2) 4 (9)
Perianal disease
Complex perianal disease
19 (43)
12 (27.2)
Previous Ada treatment
Steroids
Steroid-dependent
Steroid-resistant
24 (54.5)
7 (16)
3 (7)
Exclusive enteral nutrition 20 (45.4)
Immunomodulators 35 (80)
Abbreviations: Ada, adalimumab; PCDAI, Pediatric Crohn’s Disease Activity 
Index.
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so did not receive any induction doses and stopped Ifx therapy 
for allergic reactions.
The maintenance dose was 40 mg every 2 weeks. Dose 
escalation (80 mg every 2 weeks) was required in three 
patients and followed by dose de-escalation after 2 months, 
because of regaining of response. Concomitant immuno-
modulators were used in ten of 44 (22%) cases (six received 
azathioprine and four methotrexate). These agents were used 
in combination with Ada throughout the entire study period.
Follow-up
The Ada-persistence rate was 100% (44 patients), 73% (32 
patients), and 52% (23 patients) at 6, 12 and 18 months, 
respectively (Figure 1). Among persisting patients, complete 
remission was achieved in 24 (55%), 25 (78%), and 12 (52%) 
cases and a clinical response in nine (20%), four (12.5%), 
and two (8.7%) patients at 6, 12, and 18 months, respectively 
(Figure 2). Mean PCDAI scores had decreased significantly 
at 6 and 12 months (12.9 and 10.4, P<0.01; Figure 3). CRP 
median values decreased significantly from baseline through-
out the whole follow-up period (5.7 mg/dL at baseline vs 2.3 
mg/dL at 6 months vs 2.3 mg/dL at 12 months vs 2.4 mg/
dL at 18 months).
Eight of the ten patients in remission at baseline main-
tained clinical remission status throughout the whole study 
period, while two relapsed. Eighteen of 34 patients (53%) 
Figure 1 Kaplan–Meier analysis of probability of remaining on Ada therapy during follow-up.
Abbreviation: Ada, adalimumab.
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with active disease despite Ifx therapy at baseline achieved 
clinical remission during Ada treatment. (Figure 4). All pri-
mary nonresponders to Ifx reported clinical remission dur-
ing the study. Therapy discontinuation because of complete 
remission was recorded in 16 patients and for Ada failure in 
six patients. Two patients discontinued treatment because of 
serious adverse events after 6 months. These data are shown 
in Figure 5.
Steroid dependence
During Ifx treatment, 7/44 (16%) patients were steroid-
dependent and seven (16%) also on steroid therapy at the 
beginning of Ada treatment. Of all enrolled patients, during 
Ada treatment, the steroid-free remission rate was 93%, 95%, 
and 96% at 6, 12, and 18 months follow-up respectively, and 
there was no steroid dependency in any patients.
Prognostic factors
We analyzed multiple prognostic factors : sex, age and weight 
at diagnosis, time between diagnosis and first Ada injec-
tion (<2 years and >2 years), disease location at diagnosis, 
combined therapies, and reasons for Ifx withdrawal (allergic 
reaction, loss of response). Time between diagnosis and first 
Ada injection was the only factor reaching statistical signifi-
cance (P<0.01), with better prognosis for those subjects who 
started Ada within 2 years from diagnosis.
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Figure 2 Rates of clinical remission, clinical response and failure of Ada in 44 children with Crohn’s disease on Ada therapy.
Abbreviation: Ada, adalimumab.
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Growth
At baseline, the mean height of enrolled patients was 154.1 
cm (128–180 cm, mean ± SD 0.91±1.27), mean weight 44.7 
kg (24–70 kg, SD 1.3±1.54) and average BMI 18.5 kg/m2 
(13.8–25.7, SD 1.02±1.35). At the end of the study, mean 
weight was 48.8 kg (27–75 kg, SD –0.99±1.46) and average 
BMI 19.4 kg/m2 (14.3–25.9, SD –0.71±1.1), although no 
significant changes in terms of linear growth were recorded 
(mean height 157.1 [128–180] cm, SD –0.83±1.37). BMI 
showed a trend toward increase (Figure 6).
Safety profile
In our study population, two of 44 patients (4.5%) suffered 
adverse events that led to Ada discontinuation. There was a 
single case of bacterial meningitis in a patient under a com-
bination regimen (Ada plus methotrexate), whereas another 
subject was diagnosed with a central nervous system (CNS) 
malignancy (medulloblastoma). No acute reaction was 
recorded. We had only one case of self-limiting injection-
site reaction.
Discussion
Ada is an anti-TNF agent the efficacy of which in obtaining 
clinical remission in pediatric CD patients has been demon-
strated in various studies.16,23,24 However, these studies had 
some drawbacks (ie, use of different scales to assess disease 
severity, concurrent presence of naïve and Ifx-failure patients, 
short follow-up, limited sample size) that limit their general-
ization in clinical practice and the possibility of comparisons 
among them. Therefore, we decided to evaluate the efficacy 
and safety of Ada in a multicenter cohort of patients. The major 
finding of our study was that even in an anti-TNF-experienced 
population, Ada treatment induced clinical remission in more 
than half the cases, with 18 patients reverting from active dis-
ease after Ifx treatment into clinical remission at 18 months, 
including Ifx primary nonresponders. Moreover, to the best of 
Figure 5 Rates of adalimumab discontinuation due to remission or to no response.
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our knowledge, the current study had the longest follow-up 
for Ada-treated patients published in medical literature.16,23,24
At the latest follow up of 18 months, Ada had induced 
clinical remission in 52% of enrolled patients, with a remission 
rate of 78% at 12 months and 55% at 6 months. Moreover, we 
observed that 18 of the 34 patients with active disease despite 
Ifx treatment (53%) achieved clinical remission during Ada 
therapy (Figure 4). These remission rates are comparable to 
previously published data. Indeed, in Russell et al,24 the remis-
sion rate was 58% at 6 months, whereas the RESEAT study 
showed an 80% remission rate at 12 months.16 The Dutch PIBD 
Working Group reported 64% and 50% remission rates at 3.3 
and 24 months, respectively,25 whereas Fumery et al reported 
Ada efficacy in 70% of their studied population.21 These results 
have been summarized in a recent systematic review.26
Therapy discontinuation because of complete remission 
was recorded in 16 of 44 patients (36%) and for serious 
events in two patients at 6 months. On the other hand, 18% 
of patients showed no response and discontinued therapy, 
confirming previous pediatric investigations.20 In particular, 
we found that loss of response and recurrence of disease 
activity during anti-TNFα therapy may occur in 15%–28% 
of the pediatric population within 12 months of Ada therapy.20 
We observed a better remission rate at 12 months than 6 
months, mainly because six nonresponders stopped Ada 
treatment during the first 6 months.
Another important finding of our study is the high 
corticosteroid-free remission rate (96%) at the last follow-up, 
while during Ifx therapy 16% of our population was steroid-
dependent. This result is very important, because steroid use has 
significant impact on growth development in young patients. 
Indeed, in terms of the rate of linear growth, we did not find 
a significant difference in parameters considered at the end of 
treatment, both for the general cohort and the sex subgroups. 
However, we found a positive trend for BMI, with a mild 
improvement in weight gain in the female subgroup (P=0.047). 
Of note, when Ada was started, the study population had a mean 
age of 14.8 years, and thus the pubertal growth spurt already 
began. This reason could actually reflect a catch-up growth defi-
cit. Unfortunately, dual-energy X-ray absorptiometry-derived 
data, such as Z-scores, were not available for the analysis.
As to the safety of Ada therapy, in our series there were 
two major adverse events: one case of meningitis and one 
neoplasm of the CNS. In other studies, the overall serious 
adverse-event rate was 2.5%–6%, and no cases of CNS 
neoplasm were reported.26,27 In our cohort, the patient who 
developed meningitis was receiving combination therapy (Ada 
plus methotrexate) and stopped Ada after 6 months. According 
to some authors, apparently there would not be an increasing 
risk of serious infections between patients receiving combina-
tion therapy (anti-TNF plus immunomodulators) and those on 
monotherapy (OR 0.37).28 However, such data are ambiguous 
in the literature: different authors have reported a higher risk 
of opportunistic infections (OR 14.5, 95% CI 4.9–43) when 
two or three immunosuppressants were associated.29 More 
importantly, the severity of CD itself may play a role in pre-
disposition to serious infections.30,31 Severity and prolongation 
of the disease could have predisposed our patient to a serious 
infection, such as meningitis. According to this theory, he had 
active and prolonged severe disease (PCDAI 40), at the time 
of infection. Regarding our case of CNS neoplasm, a medul-
loblastoma arose in a young patient diagnosed with severe CD 
treated with Ifx as first-line therapy for 8 months, and after a 
serious allergic reaction being switched to Ada. This patient 
was never treated with immunomodulators in combination 
with anti-TNF drugs. Actually, there have been no reported 
cases of medulloblastoma or other CNS malignancies in 
patients affected by inflammatory bowel disease treated with 
anti-TNF, although it is almost impossible to correlate the use 
of anti-TNF with this type of cancer.
With regard to prognostic factors, the only variable that 
reached statistical significance was the short interval (<2 
years) between diagnosis and Ada administration. In line 
with our data, the literature reports that Ada seems to work 
more effectively when introduced in an early stage of the 
disease.32 Probably, the natural history of the disease and its 
prognosis could benefit by prompt implementation of Ada.
Some important study limitations should be noted. 
Firstly, the limited sample size (n=44) may have limited the 
statistical power of the study. Secondly, we did not evaluate 
serum drug levels of anti-Ada antibodies to investigate a 
potential mechanism of loss of response, even if a recent 
CD trial showed no advantage in steroid-free remission in 
patients in which Ifx dose was increased based on therapeu-
tic drug level.33 This study was a prospective randomized 
controlled trial that demonstrated that increasing Ifx levels 
above 3 mcg/ml did not produce higher rates of endoscopic 
or clinical remission in active luminal CD. Third, we did 
not measure fecal calprotectin to have surrogate data on the 
status of gastrointestinal mucosa. However, these latter two 
tests were not available at the time the study was undertaken 
in the majority of the centers involved.
In conclusion, our data confirm the efficacy of Ada in 
Ifx refractory/intolerant pediatric patients affected by CD. 
Longer prospective studies are warranted to define the general 
effectiveness and safety of Ada in pediatric patients with CD.
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